Heart Attack

ProSomnus® Announces FDA 510(k) Clearance for ProSomnus EVO™ [PH] Sleep and Snore Device

Device expands ProSomnus’ suite of FDA-cleared Precision Oral Appliance Therapy Devices for treatment of Obstructive Sleep Apnea (OSA) Device is engineered…

2 years ago

Avricore to Present at Emerging Growth Conference on Oct. 26, 2022

VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is excited to…

2 years ago

HealthTab™ Roll Out on Track and Operations Cashflow Positive

VANCOUVER, British Columbia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”) is pleased…

2 years ago

SomaLogic’s Chief Medical Officer Steve Williams honored with C-Suite Award by the Denver Business Journal

BOULDER, Colo., Sept. 26, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced…

2 years ago

Amryt Supports FH Awareness Day – September 24, 2022

Amryt Supports FH Awareness Day – September 24, 2022 DUBLIN, Ireland, and Boston MA, September 23, 2021, Amryt (Nasdaq: AMYT,…

2 years ago

Avricore Health Announces CEO Update Call on Sept. 22, 2022

VANCOUVER, British Columbia, Sept. 20, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is excited to…

2 years ago

Rejuvenation Startup Summit 2022 announces Program and Speakers

BERLIN, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Forever Healthy Foundation is pleased to announce the Rejuvenation Startup Summit 2022…

2 years ago

Avricore Health Reports Second-Quarter 2022 Results

VANCOUVER, British Columbia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased…

2 years ago

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

-- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and…

2 years ago

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes

-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses --…

2 years ago